Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful conscientiously but unsuccessfully to create a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last several shares of mine. The first CytoDyn article of mine, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire job interview which I came away with a poor impression of the company.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, although the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the know-how as well as connected intellectual property coming from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and also the first brand new drug program approval ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and numerous indications, it’s this individual treatments in addition to a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an active company with diverse interests albeit focused on leronlimab, several disease types, multiple publications and multiple delivering presentations.

Could all of it be smoke and mirrors? That is a question I’ve been asking myself with the really start of the interest of mine in this particular organization. Judging by way of the multiples of a huge number of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *